Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.
Explore innovative strategies for managing schizophrenia, focusing on novel treatments that address negative and cognitive symptoms beyond traditional antipsychotics.
Explore Irvin D. Yalom's impactful insights on psychotherapy, revealing the emotional dynamics between therapist and patient in transformative narratives.
Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.
AI chatbots pose significant privacy risks as user data becomes proprietary, raising concerns about exploitation and data security in a digital landscape.
Explore the vital contributions of psychiatry, from therapeutic alliances to ethical principles, and the future challenges it faces in a complex world.
AFSP's new CAPS program empowers health care professionals with essential skills to identify and support patients at risk for suicide effectively.
Frank A. Clark, MD, reflects on current events using poetry.
Learn how to critically analyze randomized controlled trials to ensure trustworthy results and improve clinical decision-making in mental health care.
Let's explore the therapeutic value of fear, including how embracing anxiety enhances creativity and personal growth in artists and therapists alike.
The article explores the psychological impact of recent mass killings, highlighting societal issues like anti-Semitism and mental health, while calling for collective healing.
Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.
A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.
Valproate's role in treating bipolar disorder is questioned as evidence suggests better alternatives exist for managing acute mania and maintenance.
Explore the psychological impact of Pantone's 2026 color choice, "Cloud Dancer," and its implications for emotional well-being and societal unity.
Postoperative delirium often goes unrecognized, especially in older patients. Early detection and intervention are crucial for better outcomes.
New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.
Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.
"But when I finally learned to feel everything, I became a psychiatrist who touches nothing but a patient’s hand at the first meeting and the final good bye..."
Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.
Psychiatric Times celebrates 40 years of impactful insights, exploring key topics in psychiatry, including medication management and emerging treatments.
Explore the challenges of protecting privacy in AI chatbots and discover expert insights on navigating data security in a profit-driven landscape.
Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.
Dr. Carrie Soloway's legacy inspires courage in transgender individuals, highlighting the ongoing challenges and triumphs in mental health and identity.
Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.
Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.
Psychiatric Times celebrates 40 years of advancing mental health care, offering insights, news, and community for psychiatric professionals. Join us in 2026!
Explore innovative solutions to combat burnout in health care, including coaching, psychedelics, and addressing administrative harm for lasting change.
Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.
American psychiatry struggles with understanding psychopathology, emphasizing the need to return to its roots for accurate diagnosis and effective treatment.
